Dosing chart / Weight & metabolic

Semaglutide dosage

Also known as: Ozempic, Wegovy

What is Semaglutide?

Semaglutide is a lab-made version of the gut hormone GLP-1, made by Novo Nordisk and first approved in the US in 2017. It is sold as Ozempic for type 2 diabetes and as Wegovy, a weekly injection or daily tablet, for weight and cardiovascular risk reduction.

How it works

It activates the GLP-1 receptor, the target of the body's own GLP-1, a hormone that regulates appetite and calorie intake. How it lowers cardiovascular risk has not been established.

What the evidence shows

In a 68-week trial of 1,961 adults with obesity or overweight, weight fell 14.9% with Wegovy injection versus 2.4% with placebo. In a trial of 17,604 adults with cardiovascular disease and overweight or obesity, it lowered the risk of a first major cardiovascular event (hazard ratio 0.80). In a 72-week trial of 1,407 adults, the higher-strength Wegovy HD produced an 18.8% loss versus 3.9% with placebo. Its approval for the liver disease MASH is accelerated and awaits a confirmatory trial. Whether it causes thyroid C-cell tumors in humans is unknown.

Reported side effects

  • Nausea
  • Diarrhea
  • Vomiting
  • Constipation
  • Abdominal pain
  • Dysesthesia (abnormal skin sensations)
  • Headache
  • Fatigue
  • Indigestion and bloating
  • Dizziness
  • Hair loss

Cautions

  • Boxed warning: causes thyroid C-cell tumors in rodents; the risk in humans is unknown.
  • Contraindicated with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.
  • Label warnings include pancreatitis, gallbladder disease, kidney injury from dehydration, severe gastrointestinal reactions, diabetic retinopathy complications, and aspiration under anesthesia.
  • May cause fetal harm; the Wegovy label advises stopping at least 2 months before a planned pregnancy when used for weight or cardiovascular risk reduction.
  • Compounded semaglutide is not FDA-approved. The FDA had received 990 adverse event reports for it as of May 31, 2026, some involving dosing errors, and warns of counterfeit Ozempic and unapproved salt forms.

Legal and regulatory status

FDA-approved. Ozempic is approved for adults with type 2 diabetes to improve blood sugar control, to reduce major cardiovascular events in those with established cardiovascular disease, and to reduce kidney and cardiovascular risks in those with chronic kidney disease. Wegovy is approved to reduce cardiovascular risk in adults with cardiovascular disease and obesity or overweight, for long-term weight reduction (injection from age 12; tablets in adults), and, as an injection, for noncirrhotic MASH with moderate to advanced liver fibrosis. WADA does not prohibit semaglutide but includes it in its 2026 Monitoring Program.

Common questions

What is the difference between Ozempic and Wegovy?

Both contain semaglutide from the same manufacturer but are approved for different uses. Ozempic is approved for adults with type 2 diabetes; Wegovy is approved for weight reduction, cardiovascular risk reduction and the liver disease MASH.

How much weight do people lose on semaglutide?

In a 68-week trial in the Wegovy label, adults lost an average of 14.9% of body weight versus 2.4% with placebo. Participants also followed a reduced-calorie diet and increased physical activity, and individual results vary.

Is compounded semaglutide the same as Ozempic or Wegovy?

No. Compounded semaglutide is not FDA-approved, so the FDA does not review it for safety, effectiveness or quality. The agency has reported dosing errors and salt forms that differ from the approved ingredient.

Sources

  1. FDA: Wegovy (semaglutide) prescribing information, revised June 2026
  2. FDA: Ozempic (semaglutide) prescribing information, revised May 2026
  3. FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
  4. NADA Germany: WADA publishes Prohibited List 2026
  5. WADA: Monitoring Program

Semaglutide reviews and Q&A

TopicRepliesLast activity

No reviews or questions yet. Be the first.

More in Weight & metabolic

Stacks that include Semaglutide

Compare Semaglutide

Reference only, not medical advice. Doses marked FDA-approved come from the US prescribing label. Doses marked Not approved are ranges reported from small studies or community use and have not been established as safe or effective in humans. Check anything here with a licensed clinician before acting on it. Read the full disclaimer.